C. Sheridan

发表

Fast, portable tests come online to curb coronavirus pandemic

C. Sheridan, 2020, Nature Biotechnology.

Illumina claims $1,000 genome win

C. Sheridan, 2014, Nature Biotechnology.

Protein chip companies turn to biomarkers

C. Sheridan, 2005, Nature Biotechnology.

IDO inhibitors move center stage in immuno-oncology

C. Sheridan, 2015, Nature Biotechnology.

Gene therapy finds its niche

C. Sheridan, Cormac Sheridan, 2011, Nature Biotechnology.

Positive clinical data in Parkinson's and ischemia buoy gene therapy

C. Sheridan, 2007, Nature Biotechnology.

Nature Biotechnology's academic spinouts of 2016

A. Bouchie, C. Sheridan, L. Defrancesco, 2017, Nature Biotechnology.

Erratum: Nature Biotechnology's academic spinouts of 2016

A. Bouchie, C. Sheridan, L. Defrancesco, 2017, Nature Biotechnology.

First approval in sight for Novartis' CAR-T therapy after panel vote

C. Sheridan, 2017, Nature Biotechnology.

Despite slow progress, bispecifics generate buzz

C. Sheridan, 2016, Nature Biotechnology.

Grail to pour $1 billion into blood test to detect early cancer

C. Sheridan, 2017, Nature Biotechnology.

SGLT2 inhibitors race to enter type-2 diabetes market

C. Sheridan, 2012, Nature Biotechnology.

Amgen swallows Micromet to BiTE into ALL market

C. Sheridan, 2012, Nature Biotechnology.

Exosome cancer diagnostic reaches market

C. Sheridan, 2016, Nature Biotechnology.

Europe lags, US leads 2nd-generation biofuels

C. Sheridan, 2008, Nature Biotechnology.

EGFR inhibitors embrace KRAS

C. Sheridan, 2008, Nature Biotechnology.

Cautious optimism surrounds early clinical data for PD-1 blocker

C. Sheridan, 2012, Nature Biotechnology.

CAR-T cells forge ahead, Novartis reorganizes

C. Sheridan, 2016, Nature Biotechnology.

Genentech to salvage anti-MET antibody with subgroup analysis

C. Sheridan, 2014, Nature Biotechnology.

FDA approvals usher in the post-interferon era in HCV

C. Sheridan, 2014, Nature Biotechnology.

Drugmakers plow more resources into autism

C. Sheridan, 2013, Nature Biotechnology.

Phase 3 data for PCSK9 inhibitor wows

C. Sheridan, 2013, Nature Biotechnology.

Firms chase diabetic inflammation with anti-IL-1β antibodies

C. Sheridan, 2010, Nature Biotechnology.

Proof of concept for next-generation nanoparticle drugs in humans

C. Sheridan, 2012, Nature Biotechnology.

Drug developers switch gears to inhibit STING

C. Sheridan, 2019, Nature Biotechnology.

Roche backs Aileron's stapled peptides

C. Sheridan, 2010, Nature Biotechnology.

CETP inhibitors boost 'good' cholesterol to no avail

C. Sheridan, 2016, Nature Biotechnology.

Vaccine market boosters

C. Sheridan, 2009, Nature Biotechnology.

First oncolytic virus edges towards approval in surprise vote

C. Sheridan, 2015, Nature Biotechnology.

Genentech obtains proof of concept for hedgehog inhibition

C. Sheridan, 2009, Nature Biotechnology.

Coronavirus testing finally gathers speed.

C. Sheridan, 2020, Nature biotechnology.

Who's who in biotech

Kendall Powell, C. Sheridan, E. Waltz, 2006, Nature Biotechnology.

First new drug approval for AML in 15 years

C. Sheridan, 2017, Nature Biotechnology.

Biogen and UPenn join forces to commercialize gene therapies

C. Sheridan, 2016, Nature Biotechnology.

Industry pursues co-stimulatory receptor immunomodulators to treat cancer

C. Sheridan, 2013, Nature Biotechnology.

Amgen announces oncolytic virus shrinks tumors

C. Sheridan, 2013, Nature Biotechnology.

A taste of the future

C. Sheridan, 2004, Nature Biotechnology.

Anti-CD20 antibody wows in multiple sclerosis

C. Sheridan, 2015, Nature Biotechnology.

Fast track to MS drug

C. Sheridan, 2004, Nature Biotechnology.

New class PCSK9 blockers stride into cholesterol market

C. Sheridan, 2015, Nature Biotechnology.

Flu vaccine makers upgrade technology—and pray for time

C. Sheridan, 2009, Nature Biotechnology.

Tysabri raises alarm bells on drug class

C. Sheridan, 2005, Nature Biotechnology.

Genentech's Ocrevus heralds new chapter in MS treatment

C. Sheridan, 2017, Nature Biotechnology.

First Axl inhibitor enters clinical trials

C. Sheridan, 2013, Nature Biotechnology.

Cardiac stem cell therapies inch toward clinical litmus test

C. Sheridan, 2013, Nature Biotechnology.

Antiinfective biotechs face partnering gap

C. Sheridan, 2005, Nature Biotechnology.

Synthetic biology firms pivot from biofuels to cheap biologics

C. Sheridan, 2016, Nature Biotechnology.

Milestone approval lifts Illumina's NGS from research into clinic

C. Sheridan, 2014, Nature Biotechnology.

Recasting natural product research

C. Sheridan, 2012, Nature Biotechnology.

New Merck and Vertex drugs raise standard of care in hepatitis C

C. Sheridan, 2011, Nature Biotechnology.

Death by inflammation: drug makers chase the master controller

C. Sheridan, 2019, Nature Biotechnology.

Billion-dollar deal propels RNAi to CNS frontier

C. Sheridan, 2019, Nature Biotechnology.

Wnt is back in drugmakers' sights, but is it druggable?

C. Sheridan, 2018, Nature Biotechnology.

Omics-driven startups challenge healthcare model

C. Sheridan, 2015, Nature Biotechnology.

Immune-checkpoint inhibitors march on, now in combinations

C. Sheridan, 2014, Nature Biotechnology.

Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance

C. Sheridan, 2016, Nature Biotechnology.

Coronavirus and the race to distribute reliable diagnostics

C. Sheridan, Cormac Sheridan, 2020, Nature Biotechnology.

Drug developers switch gears to inhibit STING

C. Sheridan, 2019, Nature Biotechnology.

Convalescent serum lines up as first-choice treatment for coronavirus

C. Sheridan, 2020, Nature Biotechnology.

Cancer centers zero in on exceptional responders

C. Sheridan, 2014, Nature Biotechnology.

FDA approves 'farmaceutical' drug from transgenic chickens

C. Sheridan, 2016, Nature Biotechnology.

Grail of RAS cancer drugs within reach

C. Sheridan, 2020, Nature Biotechnology.

Cost-effectiveness data on biologics needed

A. Katsnelson, C. Sheridan, 2005, Nature Biotechnology.

EU to review rare disease drugs market exclusivity

C. Sheridan, 2004, Nature Biotechnology.

COVID-19 spurs wave of innovative diagnostics

C. Sheridan, 2020, Nature Biotechnology.

Drug developers refocus efforts on RAS

C. Sheridan, 2016, Nature Biotechnology.

Oncologists greet Lumakras: the world’s first KRAS inhibitor

C. Sheridan, 2021, Nature Biotechnology.

First COVID-19 DNA vaccine approved, others in hot pursuit

C. Sheridan, 2021, Nature Biotechnology.

Questions swirl around failures of disease-modifying Huntington’s drugs

C. Sheridan, 2021, Nature Biotechnology.

With Alnylam's amyloidosis success, RNAi approval hopes soar

C. Sheridan, 2017, Nature Biotechnology.

First off-the-shelf mesenchymal stem cell therapy nears European approval

C. Sheridan, 2018, Nature Biotechnology.

Allogene and Celularity move CAR-T therapy off the shelf

C. Sheridan, 2018, Nature Biotechnology.

Genentech raises stakes on PARP inhibitors

C. Sheridan, 2006, Nature Biotechnology.

Grail of RAS cancer drugs within reach

C. Sheridan, 2020, Nature Biotechnology.

Kenyan dispute illuminates bioprospecting difficulties

C. Sheridan, Cormac Sheridan, 2004, Nature Biotechnology.

Making green

C. Sheridan, 2009, Nature Biotechnology.

Bispecific antibodies poised to deliver wave of cancer therapies

C. Sheridan, 2021, Nature Biotechnology.

Correction: Corrigendum: Industry continues dabbling with open innovation models

C. Sheridan, 2012, Nature Biotechnology.

Industry continues dabbling with open innovation models

C. Sheridan, 2011, Nature Biotechnology.

Doubts raised over 'read-through' Duchenne drug mechanism

C. Sheridan, 2013, Nature Biotechnology.

First integrin inhibitor since Tysabri nears approval for IBD

C. Sheridan, 2014, Nature Biotechnology.

Tysabri back on market

C. Sheridan, 2006, Nature Biotechnology.

Amgen's bispecific antibody puffs across finish line

C. Sheridan, 2015, Nature Biotechnology.

Antibiotics au naturel

C. Sheridan, 2006, Nature Biotechnology.

Pancreatic cancer provides testbed for first mechanotherapeutics

C. Sheridan, 2019, Nature Biotechnology.

Biotrin assay to monitor cervical cancer exposure rates

C. Sheridan, 2007, Nature Biotechnology.

Amgen's angiopoietin blocker fails in ovarian cancer

C. Sheridan, 2015, Nature Biotechnology.

Sangamo's landmark genome editing trial gets mixed reception

C. Sheridan, 2018, Nature Biotechnology.

Pivotal trials for β-secretase inhibitors in Alzheimer's

C. Sheridan, 2015, Nature Biotechnology.

Investors keep the faith in cancer liquid biopsies

C. Sheridan, 2019, Nature Biotechnology.

Mammoth, Arbor and Beam launch new wave of CRISPR startups

C. Sheridan, 2018, Nature Biotechnology.

CRISPR therapeutics push into human testing

C. Sheridan, 2017, Nature Biotechnology.

A reprieve from hemophilia A, but for how long?

C. Sheridan, 2020, Nature Biotechnology.

Go-ahead for first in-body CRISPR medicine testing

C. Sheridan, 2018 .

Nature Biotechnology’s academic spinouts of 2018

K. Garber, C. Sheridan, L. Defrancesco, 2019, Nature Biotechnology.

Doubts surround link between Bt cotton failure and farmer suicide

C. Sheridan, 2009, Nature Biotechnology.

Investors start backing hearing loss treatments

C. Sheridan, 2013, Nature Biotechnology.

Fresh from the biologic pipeline—2009

C. Sheridan, 2010, Nature Biotechnology.

TeGenero fiasco prompts regulatory rethink

C. Sheridan, Cormac Sheridan, 2006, Nature Biotechnology.

Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare

C. Sheridan, 2021, Nature biotechnology.

First-in-class cancer therapeutic to stimulate natural killer cells.

C. Sheridan, 2006, Nature biotechnology.

First PD-1 inhibitor breezes across finish line

C. Sheridan, 2014, Nature Biotechnology.

Footrace to clinic heats up for T-cell nuclear receptor inhibitors

C. Sheridan, 2013, Nature Biotechnology.

Stem cell therapy clears first hurdle in AMD

C. Sheridan, Cormac Sheridan, 2014, Nature Biotechnology.

To win at gene therapy, companies pick viruses with production credentials

C. Sheridan, 2019, Nature Biotechnology.

First small-molecule drug targeting RNA gains momentum

C. Sheridan, 2021, Nature biotechnology.

Death by inflammation: drug makers chase the master controller

C. Sheridan, 2019, Nature Biotechnology.

The business of making vaccines

C. Sheridan, Cormac Sheridan, 2005, Nature Biotechnology.

Drug makers target ubiquitin proteasome pathway anew

C. Sheridan, 2015, Nature Biotechnology.

CRISPR germline editing reverberates through biotech industry

C. Sheridan, 2015, Nature Biotechnology.

RNA drugs lower lipoprotein(a) and genetically driven cholesterol

C. Sheridan, 2022, Nature Biotechnology.

Erratum: Gene therapy finds its niche

C. Sheridan, 2011, Nature Biotechnology.

Glial cells on the radar

C. Sheridan, 2009, Nature Biotechnology.

Small molecule challenges dominance of TNF-α inhibitors

C. Sheridan, 2008, Nature Biotechnology.

Genetic medicines aim straight for the heart

C. Sheridan, 2023, Nature Biotechnology.

First cystic fibrosis drug advances towards approval

C. Sheridan, 2011, Nature Biotechnology.

Pfizer swallows Wyeth, validates niche buster

C. Sheridan, 2009, Nature Biotechnology.

Pharma consolidates its grip on post-antibody landscape

C. Sheridan, Cormac Sheridan, 2007, Nature Biotechnology.

Ablynx's nanobody fragments go places antibodies cannot

C. Sheridan, 2017, Nature Biotechnology.

Pertuzumab to bolster Roche/Genentech's breast cancer franchise?

C. Sheridan, 2011, Nature Biotechnology.

Bluebird’s CALD gene therapy poised for approval

C. Sheridan, 2022, Nature Biotechnology.

The Same Old Future

C. Sheridan, 2007 .